Pharmaceutical expenditure in Sweden

被引:12
|
作者
Henriksson, F
Hjortsberg, C
Rehnberg, C
机构
[1] Stockholm Sch Econ, Ctr Hlth Econ, S-11383 Stockholm, Sweden
[2] Swedish Inst Hlth Econ, S-22002 Lund, Sweden
关键词
age; disease categories; market segments; pharmaceutical expenditures; policy implications; reform;
D O I
10.1016/S0168-8510(99)00016-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Recently, the responsibility for prescribed pharmaceuticals in Sweden was transferred from national level to the regional health authorities (county councils). The purpose was that a closer integration and balance between pharmaceuticals and other factors of production in health care should produce better opportunities for a cost-effective use of the total health care resources. The purpose of this paper is to present a deeper analysis of pharmaceuticals as a production factor in Sweden, mainly during the 1990s, and to discuss the future development and future policy decisions in Sweden. Pharmaceuticals have increased their share of total health care expenditure in Sweden, from about 9% in 1990 to about 14% in 1995. The Swedish pharmaceutical market can be divided into sub-markets, where the prescription sub-market accounts for the greater part of pharmaceutical expenditure. Further, a few disease categories account for a larger fraction of the cost of prescribed pharmaceuticals. The importance of pharmaceuticals as a production factor also differs between different age groups. Several factors are expected to contribute to a future increase in Swedish pharmaceutical expenditure, for instance an ageing population and the rapid introduction of expensive new pharmaceuticals. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:125 / 144
页数:20
相关论文
共 50 条
  • [1] Expenditure on Unemployment Belief in Sweden
    不详
    INTERNATIONAL LABOUR REVIEW, 1927, 15 (04) : 593 - 596
  • [2] RESEARCH EXPENDITURE IN PHARMACEUTICAL INDUSTRY
    不详
    NATURE, 1964, 202 (492) : 140 - &
  • [3] EU PHARMACEUTICAL EXPENDITURE FORECAST
    Remuzat, C.
    Toumi, M.
    Vataire, A. L.
    Cetinsoy, L.
    VALUE IN HEALTH, 2013, 16 (03) : A254 - A255
  • [4] Pharmaceutical expenditure - a burning issue
    Groendal, Gerdur
    Bjoernsson, Einar S.
    LAEKNABLADID, 2013, 99 (05): : 233 - 233
  • [5] THE SUSTAINABILITY OF IRISH PHARMACEUTICAL EXPENDITURE
    Walshe, V
    Kenneally, M.
    VALUE IN HEALTH, 2013, 16 (07) : A469 - A469
  • [6] PHARMACEUTICAL EXPENDITURE, TOTAL HEALTH-CARE EXPENDITURE AND GDP
    Clemente, Jesus
    Marcuello, Carmen
    Montanes, Antonio
    HEALTH ECONOMICS, 2008, 17 (10) : 1187 - 1206
  • [7] Understanding the components of pharmaceutical expenditure-overview of pharmaceutical policies influencing expenditure across European countries
    Vogler, Sabine
    Zimmermann, Nina
    Habl, Claudia
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2013, 2 (04): : 178 - 187
  • [8] Is pharmaceutical expenditure related to the business cycles?
    Blazquez-Fernandez, Carla
    Cantarero-Prieto, David
    Pascual-Saez, Marta
    APPLIED ECONOMICS LETTERS, 2016, 23 (10) : 705 - 707
  • [9] Pharmaceutical expenditure in Spain: Cost and control
    Bastida, JL
    Mossialos, E
    INTERNATIONAL JOURNAL OF HEALTH SERVICES, 2000, 30 (03): : 597 - 616
  • [10] PHARMACEUTICAL EXPENDITURE IN PORTUGAL - POLICIES AND IMPACT
    Teixeira, I
    Mendes, Z.
    Ribeiro, S.
    Costa, S.
    VALUE IN HEALTH, 2011, 14 (07) : A345 - A345